These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32999078)

  • 1. Development of Generic Equivalence Margins for Early-Stage Implementation of Equivalence Testing for Potency Assays.
    Pflanzner T; Duan Y; Bui UN; Zhang L; Hartman SE; Kron M
    PDA J Pharm Sci Technol; 2021; 75(2):173-187. PubMed ID: 32999078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of parallelism testing for four-parameter logistic model in bioassays.
    Yang H; Kim HJ; Zhang L; Strouse RJ; Schenerman M; Jiang XR
    PDA J Pharm Sci Technol; 2012; 66(3):262-9. PubMed ID: 22634591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallelism in practice: approaches to parallelism in bioassays.
    Fleetwood K; Bursa F; Yellowlees A
    PDA J Pharm Sci Technol; 2015; 69(2):248-63. PubMed ID: 25868991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A curve similarity approach to parallelism testing in bioassay.
    Faya P; Rauk AP; Griffiths KL; Parekh B
    J Biopharm Stat; 2020 Jul; 30(4):721-733. PubMed ID: 32163316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fast and reliable test for parallelism in bioassay.
    Novick S; Yang H
    J Biopharm Stat; 2019; 29(6):1011-1023. PubMed ID: 30712462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing for parallelism in the heteroscedastic four-parameter logistic model.
    Sidik K; Jonkman JN
    J Biopharm Stat; 2016; 26(2):250-68. PubMed ID: 25629201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Validation of the Equivalence of the Cell-Based Potency Assay Method with a Mouse LD
    Yang Y; Zhang H; Yuan L; Wang S; Ma X
    Toxins (Basel); 2024 Jun; 16(6):. PubMed ID: 38922173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Lack-of-Fit Assessment as a System Suitability Test for Potency Assays.
    Li R; Cai W; Zocher M
    PDA J Pharm Sci Technol; 2017; 71(5):368-378. PubMed ID: 28624777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate bioassay, combination of bioassays, and Fieller's theorem.
    Srivastava MS
    Biometrics; 1986 Mar; 42(1):131-41. PubMed ID: 3719050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing similarity in bioanalytical methods.
    Liao JJ; Tian Y; Capen RC
    PDA J Pharm Sci Technol; 2011; 65(1):55-62. PubMed ID: 21414940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment and Completion: Implementation of Parallelism Testing for Four-Parameter Logistic Model in Bioassays.
    Sondag P; Joie R; Yang H
    PDA J Pharm Sci Technol; 2015; 69(4):467-70. PubMed ID: 26242783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics.
    Zuluaga AF; Agudelo M; Rodriguez CA; Vesga O
    BMC Clin Pharmacol; 2009 Jan; 9():1. PubMed ID: 19149891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalence testing for parallelism in the four-parameter logistic model.
    Jonkman JN; Sidik K
    J Biopharm Stat; 2009 Sep; 19(5):818-37. PubMed ID: 20183446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Method for Qualification of a Potency Assay through Partial Computer Simulation.
    Novick S; Sondag P; Schofield T; Miller K
    PDA J Pharm Sci Technol; 2018; 72(3):249-263. PubMed ID: 29444993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalence testing for similarity in bioassays using bioequivalence criteria on the relative bioactivity.
    Baljé-Volkers C; Mzolo T; Talens E; IJzerman-Boon P; Van den Heuvel E
    Pharm Stat; 2018 Feb; 17(1):12-24. PubMed ID: 29110389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of outlier tests for potency bioassays.
    Sondag P; Zeng L; Yu B; Yang H; Novick S
    Pharm Stat; 2020 May; 19(3):230-242. PubMed ID: 31762118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a statistical outlier in potency bioassays.
    Sondag P; Zeng L; Yu B; Rousseau R; Boulanger B; Yang H; Novick S
    Pharm Stat; 2018 Nov; 17(6):701-709. PubMed ID: 30112804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical equivalence by design for generic drugs: modified-release products.
    Raw AS; Lionberger R; Yu LX
    Pharm Res; 2011 Jul; 28(7):1445-53. PubMed ID: 21387150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model-free approach to estimation of relative potency in dose-response curve analysis.
    Guardabasso V; Rodbard D; Munson PJ
    Am J Physiol; 1987 Mar; 252(3 Pt 1):E357-64. PubMed ID: 3826362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case Study for Critical Reagent Qualification for Ligand Binding Assays Using Equivalence Test Methodology.
    Niemuth NA; Triplett CA; Anderson MS; Sankovich KA; Rudge TL
    AAPS J; 2023 Sep; 25(5):89. PubMed ID: 37715073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.